ReviewWorld journal of gastroenterology2021
Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Hepatocellular carcinoma risk reduction associated with antiviral treatment in patients with noncirrhotic chronic hepatitis B: a systematic literature review and comparative meta-analysis.BMC gastroenterology · 2026Pooled it
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Review
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Validity of a seven-gene signature as a non-invasive biomarker for cirrhosis: a cross-sectional study in Egyptian patients with HBV infection.BMC gastroenterology · 2026Article
- CCNA2, MAD2L1, AURKA, and PTTG1 promote proliferation and migration in hepatocellular carcinoma.BMC gastroenterology · 2026Article
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Hepatocellular Carcinoma in Africa: Epidemiology, Prevention and Outcomes.Current hepatology reports · 2026Review
- Nonlinear relationship between age and the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis.BMC infectious diseases · 2025Observational
- Hepatitis B virus infection and associated risk factors among mothers attending public health facilities in Bahir Dar, Northwest Ethiopia.Scientific reports · 2025Article
- Knowledge, attitudes, and prevention practices for hepatitis B and C virus infection among patients in the North Gondar zone, Northwest Ethiopia.Virology journal · 2025Article
- Seroprevalence of hepatitis B, hepatitis C, and HIV in pregnant women attending a tertiary care hospital in Mogadishu, Somalia, 2017-2021.BMC infectious diseases · 2025Article
- Article
- Prevalence, Molecular Characterization, and Immune Status Response of Hepatitis B Virus Among Healthcare Workers in Yaoundé General Hospital, Cameroon, During May to June 2024: A Hospital-Based Cross-Sectional Study.Health science reports · 2025Article
- When Metabolic Dysfunction-Associated Steatotic Liver Disease Meets Viral Hepatitis.Journal of clinical medicine · 2025Review
- The interplay of socio-demographic factors and disease prevalence: insights into malaria, Hepatitis B, and Hepatitis C in Lafia, Nasarawa State, Nigeria.Journal of health, population, and nutrition · 2025Article
- Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea.Scientific reports · 2025Article
- Lactylation in digestive system tumors: from mechanisms to therapeutic target.Frontiers in oncology · 2025Review
- The contribution of PrEP programmes to triple elimination efforts: a cross-sectional study of status and opportunities.Frontiers in reproductive health · 2025Article
- Nanocarriers and macrophage interaction: from a potential hurdle to an alternative therapeutic strategy.Beilstein journal of nanotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elimination of viral hepatitis in sub-Saharan Africa by 2030 is an ambitious feat. However, as stated by the World Health Organization, there are unprecedented opportunities to act and make significant contributions to the elimination target. With 60 million people chronically infected with hepatitis B virus (HBV) of whom 38800 are at risk of developing highly fatal hepatocellular carcinoma (HCC) every year, sub-Saharan Africa faces one of the greatest battles towards elimination of viral hepatitis. There is a need to examine progress in controlling the disproportionate burden of HBV-associated HCC in sub-Saharan Africa within the context of this elimination target. By scaling-up coverage of hepatitis B birth dose and early childhood vaccination, we can significantly reduce new cases of HCC by as much as 50% within the next three to five decades. Given the substantial reservoir of chronic HBV carriers however, projections show that HCC incidence and mortality rates in sub-Saharan Africa will double by 2040. This warrants urgent public health attention. The trends in the burden of HCC over the next two decades, will be determined to a large extent by progress in achieving early diagnosis and appropriate linkage to care for high-risk chronic HBV infected persons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.